http://www.cnr.it/ontology/cnr/individuo/prodotto/ID10324

Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer (Articolo in rivista)

Type

Articolo in rivista (Classe)
Prodotto della ricerca (Classe)

Label

Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer (Articolo in rivista) (literal)

Anno

2007-01-01T00:00:00+01:00 (literal)

Alternative label

Mangili G. 1, Picchio M. 2, Sironi S. 3,4, Vigano R. 1, Rabaiotti E. 1, Bornaghi D. 1, Bettinardi V. 2, Crivellaro C. 3, Messa C. 3,5,6, Fazio F. 2,5,6. (2007)
Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer
in European journal of nuclear medicine and molecular imaging (Print)
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

Mangili G. 1, Picchio M. 2, Sironi S. 3,4, Vigano R. 1, Rabaiotti E. 1, Bornaghi D. 1, Bettinardi V. 2, Crivellaro C. 3, Messa C. 3,5,6, Fazio F. 2,5,6. (literal)

Pagina inizio

658 (literal)

Pagina fine

666 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

34 (literal)

Rivista

European journal of nuclear medicine and molecular imaging (Rivista)

Note

ISI Web of Science (WOS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

1. Department of Gynaecology and Obstetrics, Scientific Institute San Raffaele, Milan, Italy 2. Department of Nuclear Medicine, Scientific Institute San Raffaele, Via Olgettina 60, 20132 Milan, Italy 3. University of Milano-Bicocca, Milan, Italy 4. Department of Diagnostic Radiology, San Gerardo Hospital, Monza, Italy 5. Department of Nuclear Medicine, San Gerardo Hospital, Monza, Italy 6. IBFM-CNR, Milan, Italy (literal)

Titolo

Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer (literal)

Abstract

Purpose The aims of this study were to compare CT with PET/CT results in patients with suspected ovarian cancer recurrence and to assess the impact of the PET/CT findings on their clinical management. Methods Thirty-two consecutive patients with suspected ovarian cancer recurrence were retrospectively included in the study. Abdominal contrast-enhanced CT and PET/CT with [18F]FDG, in addition to conventional follow-up, were performed in all 32 patients. After the comparison between CT and PET/CT results, based on clinical reports, changes in the clinical management of patients (intermodality changes) due to PET/CT information were analysed. Results Twenty of the 32 patients were positive at CT (62.5%) versus 29 (90.6%) at PET/CT. Intermodality changes in management, i.e. use of a different treatment modality, after PET/CT examination were indicated in 14/32 (44%) patients. In particular, before PET/CT study, the planned management was as follows: wait-and-see in 7/32 (22%), further instrumental examinations in 4/32 (12%), chemotherapy in 10/32 (31%), diagnostic surgical treatment in 6/32 (19%) and surgical treatment in the remaining 5/32 (16%). After PET/CT study, wait-and-see was indicated in 1/32 (3%), further instrumental examinations in 7/32 (22%), chemotherapy in 16/32 (50%), diagnostic surgical treatment in 2/32 (6%) and surgical treatment in the remaining 6/32 (19%). Conclusion Integrated PET/CT could detect tumour relapse in a higher percentage of patients than could CT. A change in the clinical management was observed in 44% of cases when PET/CT information was added to conventional follow-up findings. (literal)

Prodotto di